Hemostatic effects of hormonal stimulation in patients with metastatic prostate cancer

Medicine and Dentistry

• Neoplasm 100%
• Androgen 100%
• Prostate Cancer 100%
• Platelet 100%
• Hormonal Regulation 100%
• Hemostat 100%
• Fibrinopeptide A 100%
• Piperazine Estrone Sulfate 100%
• Fibrinogen 66%
• Blood Clotting Factor 8 66%
• Von Willebrand Factor 66%
• Fibrinolysis 66%
• Thrombocyte Factor 4 66%
• Protein C 33%
• Tumor Cell 33%
• Cancer 33%
• Fluoxymesterone 33%
• Blood Stasis 33%
• Antithrombin 33%
• Disseminated Intravascular Coagulation 33%
• Coagulating Agent 33%
• Cytotoxic Agent 33%
• Antithrombin III 33%

Keyphrases

• Fibrinogen 100%
• Hormonal Stimulation 100%
• Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 100%
• Tumor 60%
• Androgens 60%
• Fibrinopeptide A 60%
• Platelets 40%
• Coagulation 40%
• Fibrinolysis 40%
• Platelet Factor 4 40%
• Product Factors 40%
• Von Willebrand Factor Antigen 40%
• Testosterone 20%
• Chemotherapy 20%
• Tumor Cells 20%
• Experimental Protocol 20%
• Fluoxymesterone 20%
• Hemostasis 20%
• Cytotoxic Agents 20%
• Hemostatic Parameters 20%
• Hemostatic Abnormalities 20%
• Platelet Count 20%
• Disseminated Intravascular Coagulation 20%
• Coagulant Activity 20%
• C Antigen 20%
• Metastatic Malignancy 20%
• Antithrombin III (ATIII) 20%
• Product Level 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Neoplasm 100%
• Prostate Cancer 100%
• Hemostatic Agent 100%
• Androgen 75%
• Fibrinopeptide A 75%
• Estropipate 75%
• Fibrinogen 50%
• Blood Clotting Factor 8 50%
• Thrombocyte Factor 4 50%
• Von Willebrand Factor 50%
• Protein C 25%
• Chemotherapy 25%
• Fluoxymesterone 25%
• Coagulating Agent 25%
• Disseminated Intravascular Clotting 25%
• Blood Stasis 25%
• Antithrombin 25%
• Cytotoxic Agent 25%